In addition, HER-2 positive patients, who account for 20% of all GC patients (21), were not enrolled in the study, and there is also a clinical need to help these patients improve their survival, so we are conducting further prospective studies on different CPS levels, HER-2 expression levels, microsatellite status, and different ICIs. Here, ERBB2 is linked to gastric cancer.